Autologous Stem-Cell Transplantation without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah’s Witnesses Because of Jehovah’s Witnesses’ (JW) refusal of blood products, treatment challenges arise. This study represents 125 JWs with lymphoma, multiple myeloma, or amyloidosis, treated with high-dose chemotherapy and autologous stem-cell transplantation without transfusions [J Clin Oncol] Abstract Donor CD4 T Cell Diversity Determines Virus Reactivation in Patients after HLA-Matched Allogeneic Stem Cell Transplantation Scientists studied the T cell receptor beta gene rearrangements of flow cytometry-sorted CD4+ and CD8+ T cells from the peripheral blood of 23 allogeneic donors before granulocyte colony-stimulating factor administration and on the day of apheresis. [Am J Transplant] Full Article Treatment of Collagen-Induced Arthritis Using Immune Modulatory Properties of Human Mesenchymal Stem Cells Researchers investigated the potential therapeutic effects of human bone marrow-, adipose tissue-, and cord blood-derived mesenchymal stem cells (MSCs) in an experimental animal model of rheumatoid arthritis, and explored the mechanism underlying immune modulation by MSCs. [Cell Transplant] Full Article Leukemia Cell Mobilization with G-CSF plus Plerixafor during Busulfan-Fludarabine Conditioning for Allogeneic Stem Cell Transplantation Investigators compared the clinical effects and outcomes of AML/myelodysplastic syndrome study patients with 164 patients from a historical data set who received busulfan-fludarabine alone before allogeneic stem cell transplant by stratifying on cytogenetics and disease status to correct for bias. [Bone Marrow Transplant] Abstract Autologous Stem Cell Transplantation versus Novel Drugs or Conventional Chemotherapy for Patients with Relapsed Multiple Myeloma after Previous ASCT Researchers retrospectively studied the outcome of second-line treatment in multiple myeloma patients from the Nordic countries with relapse after first-line high-dose therapy and autologous stem cell transplantation (ASCT). [Bone Marrow Transplant] Abstract Experience with Alemtuzumab Fludarabine, and Melphalan Reduced Intensity Conditioning Hematopoietic Cell Transplantation in over 200 Patients with Non-Malignant Diseases Reveals Good Outcomes and that Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen Investigators conducted a retrospective study of 206 patients with metabolic diseases, non-Fanconi anemia marrow failure disorders, and primary immune deficiencies who underwent 210 consecutive RIC HCT procedures at Cincinnati Children’s Hospital. [Biol Blood Marrow Transplant] Abstract Cell Type-Dependent Variation in Paracrine Potency Determines Therapeutic Efficacy against Neonatal Hyperoxic Lung Injury Scientists determined the optimal cell type for transplantation to protect against neonatal hyperoxic lung injury. The in vitro and in vivo therapeutic efficacies and paracrine potencies of human umbilical cord blood-derived mesenchymal stromal cells, human adipose tissue-derived mesenchymal stromal cells and human umbilical cord blood mononuclear cells were compared. [Cytotherapy] Full Article Outcomes of Mismatched and Unrelated Donor Hematopoietic Stem Cell Transplantation in Fanconi Anemia Conditioned with Chemotherapy Only Investigators present their experience with 17 Fanconi anemia patients who completed mismatched related or unrelated donor hematopoietic stem cell transplantation using a non-radiation fludarabine-based preparative regimen. [Ann Hematol] Abstract |